When Febuxostat Fails to Control Gout in Severe Renal Impairment (eGFR <30 mL/min)

Clinical Scenario

This protocol targets patients with gout and severe renal impairment — defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min. In this population, several standard gout treatments carry significant risk or are contraindicated, substantially narrowing the available options.

Previous Treatment Did Not Achieve Targets

Prior to this protocol, urate-lowering therapy with febuxostat was attempted. The required targets — serum uric acid below 6 mg/dL, and below 5 mg/dL in patients with severe gout — were not reached. This protocol defines the next clinical step after that failure.

Next-Step Approach (Partial Overview)

For patients with severe, debilitating chronic tophaceous gout in whom the uric acid target cannot be reached with any other available agent — including combinations — an intravenous uricase-based therapy is indicated. This approach is reserved for refractory cases meeting specific criteria; the complete regimen requires the full protocol.

Targets: Serum uric acid <6 mg/dL (360 mmol/L) and resolution of tophi.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2016-209707

Colchicine and NSAIDs should be avoided in patients with severe renal impairment.

The safe use of colchicine in patients with severe renal impairment (GFR <30 mL/min) has not been established.

Because colchicine clearance is decreased in patients with severe renal impairment, the group considered that it should be avoided in these patients, because a reduced dosage might be a source of therapeutic misuse.

In patients with renal impairment, the allopurinol maximum dosage should be adjusted to creatinine clearance.

In patients with crystal-proven, severe debilitating chronic tophaceous gout and poor quality of life, in whom the SUA target cannot be reached with any other available drug at the maximal dosage (including combinations), pegloticase is indicated.

In this study, the percentage of responders (SUA level <6 mg/dL) was 42%, on average, in patients who received pegloticase, 8 mg, every 2 weeks and 0% in the placebo group.

Effective ULT reduces the size and number of tophi and facilitates their disappearance, thereby improving the quality of life of patients with gout.

View source ↗